IL1B and neoplasm: The subset of patients that lack methylation of the IL1β locus will greatly upregulate this cytokine and could be preemptively identified by liquid biopsies for circulating tumor cells (CTC) or circulating DNA (ctDNA) combined with methodologies currently being implemented for other tumors and biomarkers (64–67).